Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model.
Allogeneic stem cell transplantations (SCT) are currently being used as a therapy for hematological malignancies, some solid tumors and nonmalignant bone marrow deficiencies. Nevertheless, clinical applicability is limited due to toxicity of conditioning regimens, graft-versus-host disease (GVHD) and the scarcity of HLA-identical family donors. New concepts are based on nonmyeloablative conditioning to reduce toxicity, prevention or amelioration of GVHD and the use of haploidentical donors to increase donor availability. To combine these requirements, we have developed a nonmyeloablative conditioning regimen, consisting of low-dose total body irradiation and cyclophosphamide-based chemotherapy. In a haploidentical F1 --> F1 mouse model, this nonmyeloablative transplantation protocol resulted in stable full donor chimerism, but also in the development of severe GVHD. Administration of keratinocyte growth factor (KGF) reduced GVHD, evident as reduced weight loss and a lesser degree of dermatitis, compared to saline-treated controls. KGF preserved plasma citrulline and tumor necrosis factor-alpha levels, both indicative for reduced injury to the gastrointestinal tract. This was confirmed by histological findings. At 6 months after transplantation, survival rates were significantly higher in KGF-treated animals as compared to phosphate buffered saline-treated controls. These results indicate that KGF preserves gut integrity and might therefore contribute substantially to reduction of lethal GVHD in (nonmyeloablative) haploidentical transplantation.
Vanclée
A
A
Department of Internal Medicine, Division of Hematology and Oncology, University Hospital Maastricht, Maastricht, The Netherlands. a.vanclee@immuno.unimaas.nl
Lutgens
L C H W
LC
Oving
E B H
EB
Deutz
N E P
NE
Gijbels
M J J
MJ
Schouten
H C
HC
Bos
G M J
GM
D000208:Acute Disease; D000818:Animals; D003872:Dermatitis / Q000517:prevention & control; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000008:administration & dosage / Q000494:pharmacology*; D005767:Gastrointestinal Diseases / Q000473:pathology / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control*; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D008297:Male; D051379:Mice; D023421:Models, Animal; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D014184:Transplantation, Homologous; D015431:Weight Loss / Q000187:drug effects
D051523:Fibroblast Growth Factor 7